In this week’s episode of "The Top Line," Fierce Deputy Editor Andrea Park and Fierce Biotech Senior Editor Gabrielle Masson discuss how workforce reductions impacted the biopharma industry in the first quarter. 

The pair examine industry trends, company closures, developments in the cell and gene space—and the reductions in force happening at federal health agencies alongside them.

To learn more about the topics in this episode: 
Biopharmas laid off staffers at least 63 times in Q1: Fierce Biotech analysis
Fierce Biotech Layoff Tracker 2025: Pfizer sells site, cuts staff; Opthea reduces workforce by 65%

 

In this week&rsquo;s episode of "The Top Line," Fierce Deputy Editor Andrea Park and Fierce Biotech Senior Editor Gabrielle Masson discuss how workforce reductions impacted the biopharma industry in the first quarter.&nbsp;
The pair examine industry trends, company closures, developments in the cell and gene space&mdash;and the reductions in force happening at federal health agencies alongside them.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/biopharmas-laid-staffers-least-61-times-q1-fierce-biotech-analysis">Biopharmas laid off staffers at least 63 times in Q1: Fierce Biotech analysis</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025">Fierce Biotech Layoff Tracker 2025: Pfizer sells site, cuts staff; Opthea reduces workforce by 65%</a></li>
</ul>
&nbsp;

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Q1 biopharma layoff trends, plus expectations for Q2

Two and a half years into his tenure as Teva’s CEO, Richard Francis is breaking down the strategy that’s powered the company through nine consecutive quarters of growth.

On this week’s episode of "The Top Line," Fierce Pharma’s Fraiser Kansteiner sits down with Francis to talk about the progress made so far on Teva’s “Pivot to Growth” strategy and what comes next. They dig into the strategies behind the company’s chief commercial medicines, its pipeline darlings and the way Teva’s generic and biosimilar backbone is expected to evolve through the end of the decade. 

To learn more about the topics in this episode: 
As Austedo, Ajovy and Uzedy gain steam, Teva banks on $5B-plus in 2030 innovative drug sales
Teva plots thousands of job cuts as restructuring drive enters 'acceleration' phase
Teva taps Matthew Shields to oversee manufacturing and supply division amid company revamp

This week's episode is sponsored by Cencora. 

Two and a half years into his tenure as Teva&rsquo;s CEO, Richard Francis is breaking down the strategy that&rsquo;s powered the company through nine consecutive quarters of growth.
On this week&rsquo;s episode of "The Top Line," Fierce Pharma&rsquo;s Fraiser Kansteiner sits down with Francis to talk about the progress made so far on Teva&rsquo;s &ldquo;Pivot to Growth&rdquo; strategy and what comes next. They dig into the strategies behind the company&rsquo;s chief commercial medicines, its pipeline darlings and the way Teva&rsquo;s generic and biosimilar backbone is expected to evolve through the end of the decade.&nbsp;
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercepharma.com/pharma/austedo-ajovy-and-uzedy-gain-steam-teva-banks-5b-2030-innovative-drug-sales">As Austedo, Ajovy and Uzedy gain steam, Teva banks on $5B-plus in 2030 innovative drug sales</a></li>
<li><a href="https://www.fiercepharma.com/pharma/teva-plots-thousands-job-cuts-restructuring-drive-enters-acceleration-phase">Teva plots thousands of job cuts as restructuring drive enters 'acceleration' phase</a></li>
<li><a href="https://www.fiercepharma.com/manufacturing/teva-taps-shields-oversee-manufacturing-and-supply-division-amid-company-revamp">Teva taps Matthew Shields to oversee manufacturing and supply division amid company revamp</a></li>
</ul>
This week's episode is sponsored by <a href="https://www.cencora.com/initiatives/pharma/supporting-biopharma-breakthroughs?utm_source=fiercepharma&amp;utm_medium=audio&amp;utm_campaign=gps_100_awareness&amp;utm_content=podcast">Cencora</a>.&nbsp;

Teva’s CEO shares ‘Pivot to Growth’ progress

Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, like many of its peers, has embraced the trend head-on.

In this week’s episode of "The Top Line," Fierce Pharma’s Zoey Becker speaks with Daejin Abidoye, M.D., AbbVie’s vice president and therapeutic area head for solid tumor oncology. They discuss the company’s evolution, trends from this year’s American Society of Clinical Oncology meeting and what’s ahead for ADCs in oncology.

AbbVie, a newer player in the ADC space, recently earned FDA approval for Emrelis in adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have previously received systemic therapy. With a robust pipeline of ADCs in development, Abidoye envisions a bright future for the class—one that could herald “a new era” of cancer treatment beyond traditional chemotherapy.

To learn more about the topics in this episode: 
AbbVie advances solid tumor agenda with FDA nod for lung cancer ADC Emrelis
AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field
Replacing chemotherapy with ADCs? AbbVie rebuilds next-gen assets after Rova-T flop

Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care&mdash;and AbbVie, like many of its peers, has embraced the trend head-on.
In this week&rsquo;s episode of "The Top Line," Fierce Pharma&rsquo;s Zoey Becker speaks with Daejin Abidoye, M.D., AbbVie&rsquo;s vice president and therapeutic area head for solid tumor oncology. They discuss the company&rsquo;s evolution, trends from this year&rsquo;s American Society of Clinical Oncology meeting and what&rsquo;s ahead for ADCs in oncology.
AbbVie, a newer player in the ADC space, recently earned FDA approval for Emrelis in adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have previously received systemic therapy. With a robust pipeline of ADCs in development, Abidoye envisions a bright future for the class&mdash;one that could herald &ldquo;a new era&rdquo; of cancer treatment beyond traditional chemotherapy.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercepharma.com/pharma/abbvie-advances-solid-tumor-agenda-fda-nod-lung-cancer-adc-emrelis">AbbVie advances solid tumor agenda with FDA nod for lung cancer ADC Emrelis</a></li>
<li><a href="https://www.fiercepharma.com/pharma/abbvie-pays-10b-acquire-immunogen-doubling-down-red-hot-adc-cancer-field">AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/asco-replacing-chemotherapy-adcs-abbvie-rebuilds-next-gen-assets-after-rova-t-flop">Replacing chemotherapy with ADCs? AbbVie rebuilds next-gen assets after Rova-T flop</a></li>
</ul>

AbbVie, ADCs and the future of cancer care

Every year, the Fierce Medtech team highlights 15 standout companies that are pushing the boundaries of innovation in medical technology. From reinventing diagnostics and surgical tools to advancing AI and biological research, this year’s Fierce 15 is full of startups rethinking what care should look like—and improving on what came before.

In this episode of "The Top Line," Fierce Medtech Senior Editor Conor Hale breaks down the themes and standout trends from this year’s list, offering a closer look at the ideas and technologies reshaping the healthcare landscape.

To learn more about the topics in this episode: 
Introducing Fierce Medtech's Fierce 15

This episode is sponsored by Cencora. 

Every year, the Fierce Medtech team highlights 15 standout companies that are pushing the boundaries of innovation in medical technology. From reinventing diagnostics and surgical tools to advancing AI and biological research, this year&rsquo;s Fierce 15 is full of startups rethinking what care should look like&mdash;and improving on what came before.
In this episode of "The Top Line," Fierce Medtech Senior Editor Conor Hale breaks down the themes and standout trends from this year&rsquo;s list, offering a closer look at the ideas and technologies reshaping the healthcare landscape.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercebiotech.com/special-reports/introducing-fierce-medtechs-fierce-15">Introducing Fierce Medtech's Fierce 15</a></li>
</ul>
This episode is sponsored by <a href="https://www.cencora.com/initiatives/pharma/supporting-biopharma-breakthroughs?utm_source=fiercepharma&amp;utm_medium=audio&amp;utm_campaign=gps_100_awareness&amp;utm_content=podcast">Cencora</a>.&nbsp;

Q1 biopharma layoff trends, plus expectations for Q2

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips